☰

Howard L. McLeod - Publications

Affiliations: 
Biology & Biomedical Sciences (Human & Statistical Genetics) Washington University, Saint Louis, St. Louis, MO 
Area:
Genetics, Bioinformatics Biology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

342 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Innocenti F, Sibley AB, Patil SA, Etheridge AS, Jiang C, Ou FS, Howell S, Plummer SJ, Casey G, Bertagnolli MM, McLeod HL, Auman JT, Blanke CD, Furukawa Y, Venook AP, et al. Genomic analysis of germline variation associated with survival of colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32958699 DOI: 10.1158/1078-0432.Ccr-20-2021  0.374
2020 Chua KC, Xiong C, Ho C, Mushiroda T, Jiang C, Mulkey F, Lai D, Schneider BP, Rashkin SR, Witte JS, Friedman PN, Ratain MJ, McLeod HL, Rugo HS, Shulman LN, et al. Genome-Wide Meta-Analysis Validates a Roless for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. Clinical Pharmacology and Therapeutics. PMID 32562552 DOI: 10.1002/Cpt.1958  0.379
2020 Walko CM, Dickey A, Motsinger-Reif AA, Scholl E, McLeod HL, Hauser RS, Van Londen GJ, Singh H, Simon J. Treatment trends with immune checkpoint inhibitor (ICI) therapy in older adults with lung cancer. Journal of Clinical Oncology. 38: e24016-e24016. DOI: 10.1200/Jco.2020.38.15_Suppl.E24016  0.339
2019 Roell KR, Havener TM, Reif DM, Jack J, McLeod HL, Wiltshire T, Motsinger-Reif AA. Synergistic Chemotherapy Drug Response Is a Genetic Trait in Lymphoblastoid Cell Lines. Frontiers in Genetics. 10: 829. PMID 31681399 DOI: 10.3389/Fgene.2019.00829  0.357
2019 Hicks JK, Quilitz RE, Komrokji RS, Kubal TE, Lancet JE, Pasikhova Y, Qin D, So W, Caceres G, Kelly K, Salchert YS, Shahbazian K, Abbas-Aghababazadeh F, Fridley BL, Velez AP, ... McLeod HL, et al. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Neutropenic AML Patients Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. Clinical Pharmacology and Therapeutics. PMID 31549389 DOI: 10.1002/Cpt.1641  0.311
2019 Hicks JK, McLeod HL. Probabilistic medicine: a pre-emptive approach is needed for cancer therapeutic risk mitigation. Biomarkers in Medicine. PMID 31385527 DOI: 10.2217/Bmm-2019-0228  0.304
2019 Fradley MG, Gliksman M, Emole J, Viganego F, Rhea I, Welter-Frost A, Armanious M, Lee DH, Walko C, Shah B, Chavez JC, McLeod H, Pinilla-Ibarz J, Schabath MB. Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. The American Journal of Cardiology. PMID 31208701 DOI: 10.1016/J.Amjcard.2019.05.029  0.342
2019 Dorsey SG, Kleckner IR, Barton D, Mustian K, O'Mara A, St Germain D, Cavaletti G, Danhauer SC, Hershman D, Hohmann AG, Hoke A, Hopkins JO, Kelly KP, Loprinzi CL, McLeod HL, et al. NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. Journal of the National Cancer Institute. PMID 30715378 DOI: 10.1093/Jnci/Djz011  0.306
2018 Innocenti F, Jiang C, Sibley AB, Denning S, Etheridge AS, Watson D, Niedzwiecki D, Hatch AJ, Hurwitz H, Nixon A, Furukawa Y, Kubo M, Crona DJ, Kindler H, McLeod HL, et al. A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii661-viii662. PMID 32137805 DOI: 10.1093/Annonc/Mdy303.038  0.341
2018 Akhtari FS, Havener TM, Fukudo M, Jack JR, McLeod HL, Wiltshire T, Motsinger-Reif AA. The influence of Neanderthal alleles on cytotoxic response. Peerj. 6: e5691. PMID 30386687 DOI: 10.7717/Peerj.5691  0.4
2018 Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, et al. A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clinical Pharmacology and Therapeutics. PMID 30260474 DOI: 10.1002/Cpt.1241  0.361
2018 Ramamoorthy A, Knepper TC, Merenda C, Mendoza M, McLeod HL, Bull J, Zhang L, Pacanowski M. Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017. Clinical Pharmacology and Therapeutics. PMID 30218447 DOI: 10.1002/Cpt.1180  0.328
2018 Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, Gao H, Mychaleckyi JC, McLeod HL, Doria A, Giacomini KM, et al. Genetic Variants in and are Associated with Variation in Response to Metformin in Individuals with Type 2 Diabetes. Diabetes. PMID 29650774 DOI: 10.2337/Db17-1164  0.312
2018 Patel JN, Wiebe LA, Dunnenberger HM, McLeod HL. Value of Supportive Care Pharmacogenomics in Oncology Practice. The Oncologist. PMID 29622698 DOI: 10.1634/Theoncologist.2017-0599  0.364
2018 Puri S, Hyland KA, Weiss KC, Bell GC, Gray JE, Kim R, Lin HY, Hoogland AI, Gonzalez BD, Nelson AM, Kinney AY, Fischer SM, Li D, Jacobsen PB, McLeod HL, et al. Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 29546524 DOI: 10.1007/S00520-018-4120-6  0.331
2018 Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clinical Pharmacology and Therapeutics. PMID 29385237 DOI: 10.1002/Cpt.1007  0.384
2017 Jack J, Small GW, Brown CC, Havener TM, McLeod HL, Motsinger-Reif AA, Richards KL. Gene expression and linkage analysis implicate CBLB as a mediator of rituximab resistance. The Pharmacogenomics Journal. PMID 29205205 DOI: 10.1038/Tpj.2017.41  0.323
2017 Williams GR, Deal AM, Shachar SS, Walko CM, Patel JN, O'Neil B, McLeod HL, Weinberg MS, Choi SK, Muss HB, Sanoff HK. The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. Cancer Chemotherapy and Pharmacology. PMID 29159476 DOI: 10.1007/S00280-017-3487-2  0.335
2017 Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology and Therapeutics. PMID 29152729 DOI: 10.1002/Cpt.911  0.307
2017 Manolio TA, Hutter CM, Avigan M, Cibotti R, Davis RL, Denny JC, Grenade L, Wheatley LM, Carrington MN, Chantratita W, Chung WH, Dalton AD, Hung SI, Lee MTM, Leeder JS, ... ... McLeod HL, et al. Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. Clinical Pharmacology and Therapeutics. PMID 29105735 DOI: 10.1002/Cpt.890  0.315
2017 Rotroff DM, Pijut SS, Marvel SW, Jack JR, Havener TM, Pujol A, Schluter A, Graf GA, Ginsberg HN, Shah HS, Gao H, Morieri ML, Doria A, Mychaleckyi JC, McLeod HL, et al. Genetic variants in HSD17B3, SMAD3, and IPO11 impact circulating lipids in response to fenofibrate in individuals with type 2 diabetes. Clinical Pharmacology and Therapeutics. PMID 28736931 DOI: 10.1002/Cpt.798  0.324
2017 Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL. Incidence and triggers of Stevens-Johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort. The Journal of Investigative Dermatology. PMID 28549953 DOI: 10.1016/J.Jid.2017.05.010  0.322
2017 Manolio TA, Fowler DM, Starita LM, Haendel MA, MacArthur DG, Biesecker LG, Worthey E, Chisholm RL, Green ED, Jacob HJ, McLeod HL, Roden D, Rodriguez LL, Williams MS, Cooper GM, et al. Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research. Cell. 169: 6-12. PMID 28340351 DOI: 10.1016/J.Cell.2017.03.005  0.308
2017 Vela CM, Knepper TC, Gillis NK, Walko CM, McLeod HL, Hicks JK. Quantitation of Targetable Somatic Mutations among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use. Pharmacotherapy. PMID 28235141 DOI: 10.1002/Phar.1917  0.335
2017 Knepper TC, Bell GC, Kevin Hicks J, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. The Oncologist. PMID 28179575 DOI: 10.1634/Theoncologist.2016-0195  0.311
2017 Mason NT, Khushalani NI, Antonia SJ, McLeod HL. Incidence and average cost per toxicity in patients treated with nivolumab. Journal of Clinical Oncology. 35: 93-93. DOI: 10.1200/Jco.2017.35.7_Suppl.93  0.341
2017 McLeod HL, Berglund AE, Yao J, Avedon M, Teer JK. The pan-cancer, pan-biomarker landscape for precision immuno-oncology. Journal of Clinical Oncology. 35: 43-43. DOI: 10.1200/Jco.2017.35.7_Suppl.43  0.366
2017 Knepper TC, Teer JK, Walko CM, McLeod HL. Pan-cancer opportunities for off-label immunotherapy based on nonsynonymous mutation burden. Journal of Clinical Oncology. 35: 14-14. DOI: 10.1200/Jco.2017.35.7_Suppl.14  0.328
2017 Williams GR, Deal AM, Shachar SS, Walko CM, Patel JN, O'Neil BH, McLeod HL, Weinberg M, Choi SK, Muss HB, Sanoff HK. The impact of sarcopenia on toxicity and pharmacokinetics of 5-fluorouracil (5FU) in colorectal cancer. Journal of Clinical Oncology. 35: 633-633. DOI: 10.1200/Jco.2017.35.4_Suppl.633  0.306
2017 McLeod HL, Patel JN, Wei M, Rosenberg Z. Level of burden of supportive care-relevant pharmacogenetic markers in general population. Journal of Clinical Oncology. 35: 221-221. DOI: 10.1200/Jco.2017.35.31_Suppl.221  0.367
2017 Mason NT, Antonia SJ, Khushalani NI, McLeod HL. Comparison of incidence and average cost per toxicity in patients treated with nivolumab and pembrolizumab. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E18292  0.316
2017 Wang W, Liao P, Xie S, Shen D, Zhou C, Mcleod H, He Y. Abstract 4567: Immunoclassification of gastric cancer in the context of clinical outcome Cancer Research. 77: 4567-4567. DOI: 10.1158/1538-7445.Am2017-4567  0.331
2016 Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ. Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy. Clinical Pharmacology and Therapeutics. PMID 27981572 DOI: 10.1002/Cpt.583  0.321
2016 Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. The Lancet. Oncology. PMID 27927582 DOI: 10.1016/S1470-2045(16)30627-1  0.332
2016 Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Graham M, Peppercorn JM, ... ... McLeod HL, et al. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. The Oncologist. PMID 27226358 DOI: 10.1634/Theoncologist.2015-0480  0.312
2016 Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel JN, Halabi S, Furukawa Y, Wheeler HE, Sibley A, Lassiter C, Weisman LS, Watson D, Krens SD, ... ... McLeod HL, et al. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27143689 DOI: 10.1158/1078-0432.Ccr-15-2823  0.347
2016 Wieren EV, Kidwell KM, Desta Z, McLeod HL, Carey LA, Irvin WJ, Hertz DL. Assessment of a clinical and genetic algorithm to predict endoxifen concentration. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E12021  0.301
2016 Innocenti F, Owzar K, Jiang C, Sibley A, Mulkey F, Carey LA, Tripathy D, Schneider BP, Barry WT, Winer EP, Hudis CA, McLeod HL, Dickler MN. A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503. Journal of Clinical Oncology. 34: 538-538. DOI: 10.1200/Jco.2016.34.15_Suppl.538  0.34
2016 Gillis NK, Ball M, Zhang Q, Zhao Y, Yoder S, Balasis ME, Mesa TE, Sallman D, Lancet JE, Komrokji RS, List AF, McLeod HL, Rollison DE, Padron E. Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly Blood. 128: 295-295. DOI: 10.1182/Blood.V128.22.295.295  0.318
2016 Hertz D, Danko W, Deal A, Walko C, Flockhart D, McLeod H, Ibrahim J, Irvin W. Abstract P5-12-06: Comprehensive assessment of the effect of genetic polymorphisms in drug metabolizing enzymes and transporters on tamoxifen activation to endoxifen Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P5-12-06  0.405
2016 Gillis NK, Bell GC, McLeod HL, Brandt AJ. Abstract 4304: Prevalence and triggers of drug-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in a cancer patient cohort Cancer Research. 76: 4304-4304. DOI: 10.1158/1538-7445.Am2016-4304  0.376
2016 Patel JN, Jiang C, Owzar K, Hertz DL, Mulkey FA, Kelly WK, Halabi S, Furukawa Y, Lassiter C, Dorsey SG, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, ... ... McLeod HL, et al. Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance) Cancer Research. 76: 2037-2037. DOI: 10.1158/1538-7445.Am2016-2037  0.378
2016 Jack J, Small G, Havener T, Brown C, McLeod H, Motsinger A, Richards KL. Abstract 1487: Gene expression and linkage analysis implicates CBLB as a mediator of rituximab resistance Cancer Research. 76: 1487-1487. DOI: 10.1158/1538-7445.Am2016-1487  0.337
2016 Tarcic G, Walko C, McLeod H, Hicks J, Barbash Z, Edelheit O, Miron B, Vidne M, Padron E. Functional characterization of variants of unknown significance (VUS) in patients and their responsiveness to targeted therapy drugs (TTD) Annals of Oncology. 27: vi403. DOI: 10.1093/Annonc/Mdw380.09  0.324
2015 Bell GC, Donovan KA, McLeod HL. Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer. Cancer Control : Journal of the Moffitt Cancer Center. 22: 426-32. PMID 26678969 DOI: 10.1177/107327481502200408  0.333
2015 He RH, He YJ, Tang YJ, Zhou HH, McLeod HL, Liu J. The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference. Pharmacogenomics. PMID 26652861 DOI: 10.2217/Pgs.15.152  0.34
2015 Hertz DL, McLeod HL. Integrated Patient and Tumor Genetic Testing for Individualized Cancer Therapy. Clinical Pharmacology and Therapeutics. PMID 26537014 DOI: 10.1002/Cpt.294  0.363
2015 Jittikoon J, Mahasirimongkol S, Charoenyingwattana A, Chaikledkaew U, Tragulpiankit P, Mangmool S, Inunchot W, Somboonyosdes C, Wichukchinda N, Sawanpanyalert P, He Y, McLeod HL, Chantratita W. Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. Journal of Human Genetics. PMID 26423926 DOI: 10.1038/Jhg.2015.115  0.367
2015 Jack J, Havener TM, McLeod HL, Motsinger-Reif AA, Foster M. Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations. Pharmacogenomics. 16: 1451-63. PMID 26314407 DOI: 10.2217/Pgs.15.85  0.352
2015 Mason NT, Bell GC, Quilitz RE, Greene JN, McLeod HL. Budget impact analysis of CYP2C19-guided voriconazole prophylaxis in AML. The Journal of Antimicrobial Chemotherapy. PMID 26233624 DOI: 10.1093/Jac/Dkv224  0.317
2015 He YJ, Winham SJ, Hoskins JM, Glass S, Paul J, Brown R, Motsinger-Reif A, McLeod HL. Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial. The Pharmacogenomics Journal. PMID 26194361 DOI: 10.1038/Tpj.2015.52  0.421
2015 Dressler LG, Deal AM, Owzar K, Watson D, Donahue K, Friedman PN, Ratain MJ, McLeod HL. Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). Journal of the National Cancer Institute. 107. PMID 26160883 DOI: 10.1093/Jnci/Djv188  0.332
2015 Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, et al. In Vivo Assessment of the Metabolic Activity of CYP2D6 Diplotypes and Alleles. British Journal of Clinical Pharmacology. PMID 25907378 DOI: 10.1111/Bcp.12665  0.315
2015 Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 121: 1025-31. PMID 25417775 DOI: 10.1002/Cncr.29169  0.323
2015 Mason NT, Bell GC, Quilitz RE, Greene JN, McLeod HL. Budget impact analysis of CYP2C19 genotyping to guide voriconazole prophylaxis in acute myeloid leukemia (AML). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E17777  0.33
2015 Innocenti F, Owzar K, Jiang C, Sibley A, Niedzwiecki D, Lenz H, Bertagnolli MM, Friedman PN, Furukawa Y, Kubo M, Ratain MJ, Blanke CD, Venook AP, McLeod HL. A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405. Journal of Clinical Oncology. 33: 3599-3599. DOI: 10.1200/Jco.2015.33.15_Suppl.3599  0.376
2015 Knepper TC, Walko CM, Bell GC, Padron E, Teer JK, McLeod HL. The landscape for genetic eligibility to basket clinical trials. Journal of Clinical Oncology. 33: 1530-1530. DOI: 10.1200/Jco.2015.33.15_Suppl.1530  0.335
2015 Jack J, Havener TM, McLeod HL, Motsinger-Reif AA, Foster M. Abstract LB-246: Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-246  0.357
2015 Innocenti F, Owzar K, Chen J, Sibley A, Niedzwiecki D, Bertagnolli M, Friedman P, Furukawa Y, Kubo M, Ratain M, Blanke C, Heinz-Josef L, Venook A, McLeod H. 2007 A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405 European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)30932-7  0.351
2014 Dressler LG, Deal AM, Patel J, Markey J, Riper MV, McLeod HL. Cancer pharmacogenomics, adoption by oncologists and patient benefit. Personalized Medicine. 11: 143-153. PMID 29751378 DOI: 10.2217/Pme.14.1  0.323
2014 Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. Plos One. 9: e107424. PMID 25232828 DOI: 10.1371/Journal.Pone.0107424  0.359
2014 Patel JN, O'Neil BH, Deal AM, Ibrahim JG, Sherrill GB, Olajide OA, Atluri PM, Inzerillo JJ, Chay CH, McLeod HL, Walko CM. A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. The Oncologist. 19: 959-65. PMID 25117066 DOI: 10.1634/Theoncologist.2014-0132  0.335
2014 Walko CM, McLeod HL. Personalizing medicine in geriatric oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2581-6. PMID 25071134 DOI: 10.1200/Jco.2014.55.9047  0.369
2014 Hariani GD, Lam ET, Lam EJ, Havener T, Kwok PY, McLeod HL, Wagner MJ, Motsinger-Reif AA. Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics. Bmc Research Notes. 7: 360. PMID 24924344 DOI: 10.1186/1756-0500-7-360  0.367
2014 Liu MZ, McLeod HL, He FZ, Chen XP, Zhou HH, Shu Y, Zhang W. Epigenetic perspectives on cancer chemotherapy response. Pharmacogenomics. 15: 699-715. PMID 24798726 DOI: 10.2217/Pgs.14.41  0.334
2014 Relling MV, McDonagh EM, Chang T, Caudle KE, McLeod HL, Haidar CE, Klein T, Luzzatto L. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clinical Pharmacology and Therapeutics. 96: 169-74. PMID 24787449 DOI: 10.1038/Clpt.2014.97  0.325
2014 Sanoff HK, Renfro LA, Poonnen P, Ambadwar P, Sargent DJ, Goldberg RM, McLeod H. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer. Plos One. 9: e94727. PMID 24727911 DOI: 10.1371/Journal.Pone.0094727  0.348
2014 Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, ... McLeod H, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1031-9. PMID 24590654 DOI: 10.1200/Jco.2013.51.1857  0.317
2014 Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, McLeod HL, Ratain MJ, Shulman LN, et al. Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). The Pharmacogenomics Journal. 14: 336-42. PMID 24513692 DOI: 10.1038/Tpj.2014.2  0.326
2014 Brewer NT, Defrank JT, Chiu WK, Ibrahim JG, Walko CM, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Peppercorn JM, McLeod HL, Carey LA, et al. Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. Public Health Genomics. 17: 43-7. PMID 24457521 DOI: 10.1200/Jco.2011.29.15_Suppl.6029  0.359
2014 Ramos E, Doumatey A, Elkahloun AG, Shriner D, Huang H, Chen G, Zhou J, McLeod H, Adeyemo A, Rotimi CN. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics Journal. 14: 217-222. PMID 23835662 DOI: 10.1038/Tpj.2013.24  0.347
2014 Patel JN, Mandock K, McLeod HL. Clinically relevant cancer biomarkers and pharmacogenetic assays. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 20: 65-72. PMID 23353710 DOI: 10.1177/1078155212473862  0.357
2014 Tan BR, Wu N, Wang-Gillam A, Suresh R, Picus J, Baranda JC, Lockhart AC, McLeod HL. Final results of the UGT1A1-based dose modification of irinotecan and its impact on rates of severe neutropenia and hospitalization. Journal of Clinical Oncology. 32: 461-461. DOI: 10.1200/Jco.2014.32.3_Suppl.461  0.36
2014 Patel JN, Jiang C, Hertz DL, Mulkey F, Friedman PN, Halabi S, Ratain MJ, Morris MJ, Small EJ, Owzar K, Kelly WK, McLeod HL. Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E16061  0.325
2014 Hertz DL, Jiang C, Owzar K, Halabi S, Kelly WK, Mulkey F, Patel JN, Carducci MA, Kelley MJ, Stadler WM, Mohamed MK, Morris MJ, Nakamura Y, Zembutsu H, Ratain MJ, ... McLeod HL, et al. A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). Journal of Clinical Oncology. 32: 9612-9612. DOI: 10.1200/Jco.2014.32.15_Suppl.9612  0.319
2014 Patel JN, Jiang C, Hertz DL, Mulkey FA, Friedman PN, Halabi S, Ratain MJ, Morris MJ, Small EJ, Owzar K, Kelly WK, McLeod HL. Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE) Cancer Research. 74: 3841-3841. DOI: 10.1158/1538-7445.Am2014-3841  0.327
2013 Jonas DE, Evans JP, McLeod HL, Brode S, Lange LA, Young ML, Shilliday BB, Bardsley MM, Swinton-Jenkins NJ, Weck KE. Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics. 14: 1593-603. PMID 24088130 DOI: 10.2217/Pgs.13.145  0.316
2013 Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clinical Pharmacology and Therapeutics. 94: 640-5. PMID 23988873 DOI: 10.1038/Clpt.2013.172  0.359
2013 McWhinney-Glass S, Winham SJ, Hertz DL, Yen Revollo J, Paul J, He Y, Brown R, Motsinger-Reif AA, McLeod HL. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5769-76. PMID 23963862 DOI: 10.1158/1078-0432.Ccr-13-0774  0.365
2013 Patel JN, Fuchs CS, Owzar K, Chen Z, McLeod HL. Gastric cancer pharmacogenetics: progress or old tripe? Pharmacogenomics. 14: 1053-64. PMID 23837480 DOI: 10.2217/Pgs.13.88  0.348
2013 McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. Science Translational Medicine. 5: 189sr4. PMID 23761042 DOI: 10.1126/Scitranslmed.3005785  0.316
2013 Patel JN, McLeod HL, Innocenti F. Implications of genome-wide association studies in cancer therapeutics. British Journal of Clinical Pharmacology. 76: 370-80. PMID 23701381 DOI: 10.1111/Bcp.12166  0.413
2013 Hertz DL, McLeod HL. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. Journal of Human Genetics. 58: 346-52. PMID 23677053 DOI: 10.1038/Jhg.2013.42  0.304
2013 Rudek MA, Connolly RM, Hoskins JM, Garrett-Mayer E, Jeter SC, Armstrong DK, Fetting JH, Stearns V, Wright LA, Zhao M, Watkins SP, McLeod HL, Davidson NE, Wolff AC. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Research and Treatment. 139: 135-43. PMID 23588952 DOI: 10.1007/S10549-013-2516-Z  0.336
2013 Smith CG, Naven M, Harris R, Colley J, West H, Li N, Liu Y, Adams R, Maughan TS, Nichols L, Kaplan R, Wagner MJ, McLeod HL, Cheadle JP. Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. Human Mutation. 34: 1026-34. PMID 23585368 DOI: 10.1002/Humu.22333  0.323
2013 Shahin MH, Cavallari LH, Perera MA, Khalifa SI, Misher A, Langaee T, Patel S, Perry K, Meltzer DO, McLeod HL, Johnson JA. VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thrombosis and Haemostasis. 109: 1045-50. PMID 23571513 DOI: 10.1160/Th12-10-0789  0.321
2013 Trammel M, Roederer M, Patel J, McLeod H. Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Current Oncology Reports. 15: 276-285. PMID 23512709 DOI: 10.1007/S11912-013-0312-X  0.341
2013 Gurwitz D, McLeod HL. Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypes. Pharmacogenomics. 14: 337-9. PMID 23438876 DOI: 10.2217/Pgs.13.35  0.335
2013 Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1472-8. PMID 23413280 DOI: 10.1093/Annonc/Mdt018  0.344
2013 He FZ, McLeod HL, Zhang W. Current pharmacogenomic studies on hERG potassium channels. Trends in Molecular Medicine. 19: 227-38. PMID 23369369 DOI: 10.1016/J.Molmed.2012.12.006  0.329
2013 Dressler LG, Deal AM, Watson D, Hollis D, Owzar K, Donohue K, Friedman PN, Ratain MJ, McLeod HL. Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials. Journal of Clinical Oncology. 31: 6501-6501. DOI: 10.1200/Jco.2013.31.15_Suppl.6501  0.314
2013 Patel JN, Deal AM, O'Neil BH, Ibrahim J, Sherrill GB, Davies JM, Bernard SA, Goldberg RM, Olajide OA, Atluri P, Inzerillo JJ, McLeod HL, Walko CM. Application of pharmacokinetic (PK)-guided 5-fluorouracil (FU) in clinical practice. Journal of Clinical Oncology. 31: 2595-2595. DOI: 10.1200/Jco.2013.31.15_Suppl.2595  0.309
2013 Hertz DL, Owzar K, Halabi S, Kelly WK, Zembutsu H, Jiang C, Patel JN, Watson D, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Small EJ, ... ... McLeod HL, et al. A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance). Journal of Clinical Oncology. 31: 11053-11053. DOI: 10.1200/Jco.2013.31.15_Suppl.11053  0.413
2012 Baker JJ, Aufforth R, Auman JT, Eil R, McLeod HL, Kim HJ, Meyers MO, Calvo BF, Yeh JJ. KRAS mutation as a prognostic factor in patients undergoing hepatic resection for metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 444. PMID 27983171 DOI: 10.1200/Jco.2012.30.4_Suppl.444  0.307
2012 Brown CC, Havener TM, Medina MW, Auman JT, Mangravite LM, Krauss RM, McLeod HL, Motsinger-Reif AA. A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenetics and Genomics. 22: 796-802. PMID 23047291 DOI: 10.1097/Fpc.0B013E3283589C50  0.335
2012 Hoskins JM, Ong PS, Keku TO, Galanko JA, Martin CF, Coleman CA, Wolfe M, Sandler RS, McLeod HL. Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome. Plos One. 7: e41954. PMID 22848671 DOI: 10.1371/Journal.Pone.0041954  0.35
2012 Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clinical Pharmacology and Therapeutics. 92: 112-7. PMID 22617227 DOI: 10.1038/Clpt.2012.57  0.35
2012 Hertz DL, McLeod HL, Irvin WJ. Tamoxifen and CYP2D6: a contradiction of data. The Oncologist. 17: 620-30. PMID 22531359 DOI: 10.1634/Theoncologist.2011-0418  0.342
2012 Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Research and Treatment. 134: 401-10. PMID 22527101 DOI: 10.1007/S10549-012-2054-0  0.405
2012 Walko CM, McLeod H. Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment Pharmacogenomics. 13: 691-697. PMID 22515611 DOI: 10.2217/Pgs.12.27  0.374
2012 He YJ, Shapero MH, McLeod HL. Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples. Pharmacogenetics and Genomics. 22: 322-4. PMID 22414877 DOI: 10.1097/Fpc.0B013E3283510A51  0.308
2012 Kaldate RR, Haregewoin A, Grier CE, Hamilton SA, McLeod HL. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. The Oncologist. 17: 296-302. PMID 22382460 DOI: 10.1634/Theoncologist.2011-0357  0.301
2012 Crowley JJ, Kim Y, Szatkiewicz JP, Pratt AL, Quackenbush CR, Adkins DE, van den Oord E, Bogue MA, Yang H, Wang W, Threadgill DW, de Villena FP, McLeod HL, Sullivan PF. Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mammalian Genome : Official Journal of the International Mammalian Genome Society. 23: 322-35. PMID 22207321 DOI: 10.1007/S00335-011-9385-8  0.324
2012 Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, ... McLeod HL, et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 577-84. PMID 22142827 DOI: 10.1158/1078-0432.Ccr-11-1387  0.352
2012 Won HH, Kim SR, Bang OY, Lee SC, Huh W, Ko JW, Kim HG, McLeod HL, O'Connell TM, Kim JW, Lee SY. Differentially expressed genes in human peripheral blood as potential markers for statin response. Journal of Molecular Medicine (Berlin, Germany). 90: 201-11. PMID 21947165 DOI: 10.1007/S00109-011-0818-3  0.316
2012 Patel JN, O'Neil BH, McLeod HL, Sherrill GB, Olijade O, Inzerillo JJ, Atluri P, Chay CH, Walko CM. Investigating the utilization of pharmacokinetic-guided fluorouracil in colorectal cancer. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E13109  0.323
2012 Hertz DL, Dees EC, Motsinger-Reif AA, Drobish A, Roy S, McLeod HL, Carey LA. Interrogation of polymorphisms in drug metabolism or transport genes and peripheral neuropathy during paclitaxel treatment. Journal of Clinical Oncology. 30: 10515-10515. DOI: 10.1200/Jco.2012.30.15_Suppl.10515  0.411
2012 Hertz D, Dees E, Roy S, Motsinger-Reif A, Drobish A, Clark L, McLeod H, Carey L. Abstract PD10-07: Patients carrying CYP2C8*3 are at increased risk of paclitaxel-induced neuropathy Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Pd10-07  0.388
2011 Irvin WJ, Weck KE, Walko CM, Chiu WK, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Anderson SM, Friedman KJ, Dees EC, Flockhart D, ... ... McLeod HL, et al. Comprehensive CYP2D6 genotyping in a multiracial population shows differences in allele frequencies between races. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e11095. PMID 28023164 DOI: 10.1200/Jco.2011.29.15_Suppl.E11095  0.316
2011 Talameh JA, McLeod HL. PON1 Q192R and Clopidogrel: A Case of the Winner's Curse or Inadequate Replication? Clinical Pharmacology & Therapeutics. 90: 771-774. PMID 22089342 DOI: 10.1038/Clpt.2011.226  0.332
2011 Thomas F, Motsinger-Reif AA, Hoskins JM, Dvorak A, Roy S, Alyasiri A, Myerson RJ, Fleshman JW, Tan BR, McLeod HL. Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. British Journal of Cancer. 105: 1654-62. PMID 22045187 DOI: 10.1038/Bjc.2011.442  0.377
2011 Peters EJ, Motsinger-Reif A, Havener TM, Everitt L, Hardison NE, Watson VG, Wagner M, Richards KL, Province MA, McLeod HL. Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics. 12: 1407-15. PMID 22008047 DOI: 10.2217/Pgs.11.92  0.378
2011 Hutz JE, Manning WA, Province MA, McLeod HL. Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins. Plos One. 6: e24873. PMID 21949775 DOI: 10.1371/Journal.Pone.0024873  0.301
2011 Irvin WJ, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, ... ... McLeod HL, et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3232-9. PMID 21768473 DOI: 10.1200/Jco.2010.31.4427  0.305
2011 Watson VG, Motsinger-Reif A, Hardison NE, Peters EJ, Havener TM, Everitt L, Auman JT, Comins DL, McLeod HL. Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees. Plos One. 6: e17561. PMID 21573211 DOI: 10.1371/Journal.Pone.0017561  0.339
2011 Kolesar JM, Dahlberg SE, Marsh S, McLeod HL, Johnson DH, Keller SM, Schiller JH. The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncology Reports. 25: 1765-72. PMID 21479364 DOI: 10.3892/Or.2011.1249  0.323
2011 Watson RG, McLeod HL. Pharmacogenomic contribution to drug response. Cancer Journal (Sudbury, Mass.). 17: 80-8. PMID 21427551 DOI: 10.1097/Ppo.0B013E3182147432  0.389
2011 He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes. Trends in Molecular Medicine. 17: 244-51. PMID 21388883 DOI: 10.1016/J.Molmed.2011.01.007  0.365
2011 Padgett L, O'Connor S, Roederer M, McLeod H, Ferreri S. Pharmacogenomics in a community pharmacy: ACT now. Journal of the American Pharmacists Association. 51: 189-193. PMID 21382809 DOI: 10.1331/Japha.2011.10178  0.307
2011 Carvalho L, Yu J, Schwartsmann G, McLeod HL, Fleshman JW. RNA expression of the molecular signature genes for metastasis in colorectal cancer. Oncology Reports. 25: 1321-7. PMID 21380492 DOI: 10.3892/Or.2011.1208  0.34
2011 Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, Dunnenberger HM, Marsh S, McLeod HL, Giacomini K, Becker ML, Gaedigk R, Leeder JS, Kager L, Relling MV, et al. PharmGKB summary: methotrexate pathway. Pharmacogenetics and Genomics. 21: 679-86. PMID 21317831 DOI: 10.1097/Fpc.0B013E328343Dd93  0.324
2011 Tan BR, Thomas F, Myerson RJ, Zehnbauer B, Trinkaus K, Malyapa RS, Mutch MG, Abbey EE, Alyasiry A, Fleshman JW, McLeod HL. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 875-83. PMID 21205745 DOI: 10.1200/Jco.2010.32.3212  0.373
2011 Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and Genomics. 21: 440-6. PMID 21048526 DOI: 10.1097/Fpc.0B013E32833Ffb56  0.384
2011 Lee SY, McLeod HL. Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. The Journal of Pathology. 223: 15-27. PMID 20818641 DOI: 10.1002/Path.2766  0.311
2011 He Y, Wood SJ, Paul J, Motsinger-Reif A, Auman T, Hoskins JM, Brown R, McLeod HL. Erratum: Abstract OIII-B-1: Genetic markers associated with platinum/taxanes-induced gastrointestinal toxicity in SCOTROC1 Trial (Clinical Pharmacology and Therapeutics (2011) 89 (S66) DOI:10.1038/clpt.2010.334) Clinical Pharmacology & Therapeutics. 90. DOI: 10.1038/Clpt.2011.24  0.306
2011 He Y, Wood SJ, Paul J, Motsinger-Reif A, Auman T, Hoskins JM, Brown R, McLeod HL. Genetic markers associated with platinum/taxanesinduced gastrointestinal toxicity in SCOTROC1trial Clinical Pharmacology & Therapeutics. DOI: 10.1038/Clpt.2010.326  0.42
2010 Thomas F, Hoskins JM, Dvorak A, Tan BR, McLeod HL. Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis. Pharmacogenomics. 11: 1751-6. PMID 21142919 DOI: 10.2217/Pgs.10.170  0.321
2010 Schipani A, Siccardi M, D'Avolio A, Baietto L, Simiele M, Bonora S, Rodríguez Novoa S, Cuenca L, Soriano V, Chierakul N, Saguenwong N, Chuchuttaworn C, Hoskins JM, Dvorak AM, McLeod HL, et al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrobial Agents and Chemotherapy. 54: 5242-50. PMID 20921307 DOI: 10.1128/Aac.00781-10  0.357
2010 Watson RG, Muhale F, Thorne LB, Yu J, O'Neil BH, Hoskins JM, Meyers MO, Deal AM, Ibrahim JG, Hudson ML, Walko CM, McLeod HL, Auman JT. Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. European Journal of Cancer (Oxford, England : 1990). 46: 3358-64. PMID 20727737 DOI: 10.1016/J.Ejca.2010.07.011  0.379
2010 McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3227-33. PMID 20530282 DOI: 10.1200/Jco.2009.21.7943  0.41
2010 Roederer MW, McLeod HL. Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics. 11: 633-6. PMID 20415551 DOI: 10.2217/Pgs.10.55  0.346
2010 Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, Deych E, Crankshaw M, Milligan PE, McLeod HL, Patel SR, Cavallari LH, Ridker PM, Grice GR, Miller RD, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clinical Pharmacology and Therapeutics. 87: 445-51. PMID 20200517 DOI: 10.1038/Clpt.2009.291  0.312
2010 Auman JT, McLeod HL. Colorectal cancer cell lines lack the molecular heterogeneity of clinical colorectal tumors. Clinical Colorectal Cancer. 9: 40-7. PMID 20100687 DOI: 10.3816/Ccc.2010.N.005  0.336
2010 Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, Goldhaber SZ, King CR, Giri T, McLeod HL, Glynn RJ, Gage BF. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. Journal of Thrombosis and Haemostasis : Jth. 8: 95-100. PMID 19874474 DOI: 10.1111/J.1538-7836.2009.03677.X  0.319
2010 Lee SC, Xu X, Chng WJ, Watson M, Lim YW, Wong CI, Iau P, Sukri N, Lim SE, Yap HL, Buhari SA, Tan P, Guo J, Chuah B, McLeod HL, et al. Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. Pharmacogenetics and Genomics. 19: 833-42. PMID 19809382 DOI: 10.1097/Fpc.0B013E328330A39F  0.319
2010 McLeod HL. Using patient DNA to optimize therapy in heart failure patients: a move toward perfection Heart Failure Reviews. 15: 183-185. PMID 19578990 DOI: 10.1007/S10741-009-9150-1  0.392
2010 Hertz D, Dees E, Motsinger-Reif A, Drobish A, Winham S, McLeod H, Carey L. Abstract PD07-10: Breast Cancer Patients Carrying the CYP2C8*3 Variant Are More Likely To Achieve Clinical Complete Response from Neoadjuvant Paclitaxel Treatment Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd07-10  0.314
2009 Watson RG, Muhale F, Thorne L, Yu J, O'Neil B, Hoskins JM, Myers MO, McLeod HL, Auman JT. Association of copy number variants in colorectal liver metastases with 5-fluorouracil resistance. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e14502. PMID 27963535 DOI: 10.1200/Jco.2009.27.15_Suppl.E14502  0.338
2009 McLeod HL, Myerson RJ, Zehnbauer B, Trinkaus K, Malyapa RS, Mutch MG, Abbey EE, Alyasiry A, Fleshman JW, Tan BR. TYMS genotype-directed neoadjuvant chemoradiation for rectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4028. PMID 27961521 DOI: 10.1200/Jco.2009.27.15_Suppl.4028  0.347
2009 Irvin WJ, Carey LA, Olajide O, Dees EC, Peppercorn J, Chiu WK, Walko CM, McLeod HL, Evans JP, Weck KE. Comprehensive CYP2D6 genotyping in a multiracial U.S. breast cancer population. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 553. PMID 27960668 DOI: 10.1200/Jco.2009.27.15_Suppl.553  0.352
2009 Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H, Dolan ME. Pharmacogenomic discovery using cell-based models. Pharmacological Reviews. 61: 413-29. PMID 20038569 DOI: 10.1124/Pr.109.001461  0.349
2009 Hertz DL, McLeod HL, Hoskins JM. Pharmacogenetics of breast cancer therapies. Breast (Edinburgh, Scotland). 18: S59-63. PMID 19914545 DOI: 10.1016/S0960-9776(09)70275-9  0.375
2009 Ellis KJ, Stouffer GA, McLeod HL, Lee CR. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics. 10: 1799-817. PMID 19891556 DOI: 10.2217/Pgs.09.143  0.33
2009 Goldberg RM, Sargent DJ, Morton RF, Green E, Sanoff HK, McLeod H, Buckner J. NCCTG study N9741: Leveraging learning from an NCI cooperative group phase III trial Oncologist. 14: 970-978. PMID 19828593 DOI: 10.1634/Theoncologist.2009-0175  0.329
2009 McWhinney SR, McLeod HL. Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics. 10: 489-93. PMID 19650256 DOI: 10.2217/14622416.10.3.489  0.312
2009 Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4109-15. PMID 19636001 DOI: 10.1200/Jco.2009.21.9527  0.349
2009 Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nature Reviews. Cancer. 9: 576-86. PMID 19629072 DOI: 10.1038/Nrc2683  0.361
2009 Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics. 10: 1139-46. PMID 19604089 DOI: 10.2217/Pgs.09.35  0.376
2009 Yen-Revollo JL, Van Booven DJ, Peters EJ, Hoskins JM, Engen RM, Kannall HD, Ofori-Adjei D, McLeod HL, Marsh S. Influence of ethnicity on pharmacogenetic variation in the Ghanaian population. The Pharmacogenomics Journal. 9: 373-9. PMID 19546880 DOI: 10.1038/Tpj.2009.28  0.325
2009 Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing Trends in Pharmacological Sciences. 30: 375-386. PMID 19540002 DOI: 10.1016/J.Tips.2009.05.001  0.338
2009 Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. International Journal of Radiation Oncology Biology Physics. 74: 673-688. PMID 19480968 DOI: 10.1016/J.Ijrobp.2009.03.003  0.328
2009 Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN, Coltman CA, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3540-6. PMID 19470925 DOI: 10.1200/Jco.2008.20.8793  0.365
2009 Peters EJ, Kraja AT, Lin SJ, Yen-Revollo JL, Marsh S, Province MA, McLeod HL. Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. Pharmacogenetics and Genomics. 19: 399-401. PMID 19339911 DOI: 10.1097/Fpc.0B013E328329Fdec  0.366
2009 Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. The Journal of Molecular Diagnostics : Jmd. 11: 216-25. PMID 19324988 DOI: 10.2353/Jmoldx.2009.080123  0.334
2009 Crowley JJ, Sullivan PF, McLeod HL. Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics. 10: 161-3. PMID 19207016 DOI: 10.2217/14622416.10.2.161  0.378
2009 Gurwitz D, McLeod HL. Genome-wide association studies: powerful tools for improving drug safety and efficacy. Pharmacogenomics. 10: 157-159. PMID 19207015 DOI: 10.2217/14622416.10.2.157  0.396
2009 Bhushan S, McLeod H, Walko CM. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clinical Colorectal Cancer. 8: 15-21. PMID 19203892 DOI: 10.3816/Ccc.2009.N.003  0.372
2009 Walko CM, McLeod H. Pharmacogenomic progress in individualized dosing of key drugs for cancer patients Nature Reviews Clinical Oncology. 6: 153-162. PMID 19174777 DOI: 10.1038/Ncponc1303  0.35
2009 Gresham V, McLeod HL. Genomics: applications in mechanism elucidation. Advanced Drug Delivery Reviews. 61: 369-374. PMID 19166886 DOI: 10.1016/J.Addr.2008.12.002  0.305
2009 McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Molecular Cancer Therapeutics. 8: 10-6. PMID 19139108 DOI: 10.1158/1535-7163.Mct-08-0840  0.406
2009 Irvin W, Carey L, Olajide O, Dees E, Raab R, Corso S, Chiu W, Walko C, Evans J, Weck K, McLeod H, Peppercorn J. Patients' Understanding of a CYP2D6 Tamoxifen Genotyping Study. Cancer Research. 69: 6082-6082. DOI: 10.1158/0008-5472.Sabcs-09-6082  0.334
2009 Irvin W, Carey L, Dees E, Lange L, Chiu W, Evans J, Anderson S, Freidman K, Weck K, Desta Z, Walko C, Olajide O, Raab R, Corso S, Peppercorn J, ... ... McLeod H, et al. Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population. Cancer Research. 69: 410-410. DOI: 10.1158/0008-5472.Sabcs-09-410  0.393
2008 Walko CM, Patel N, Revollo J, Whitley J, Serody J, Gabriel D, Comeau T, McLeod H, Shea TC. Influence of glutathione S-transferase A1 genotype on intravenous busulfan pharmacokinetics. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14635. PMID 27950245 DOI: 10.1200/Jco.2008.26.15_Suppl.14635  0.323
2008 McLeod HL, Owzar K, Kroetz D, Innocenti F, Das S, Friedman P, Giacomini K, Goldberg RM, Venook AP, Ratain MJ. Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3513. PMID 27949752 DOI: 10.1200/Jco.2008.26.15_Suppl.3513  0.373
2008 Tan BR, Zehnbauer B, Picus J, Fournier C, James J, Brower A, McLeod H. UGT1A1 genotype-based dose modification of irinotecan regimens: Impact on hematologic toxicities. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 13500. PMID 27948936 DOI: 10.1200/Jco.2008.26.15_Suppl.13500  0.334
2008 Sanoff HK, McLeod HL. Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics. Seminars in Colon & Rectal Surgery. 19: 226-230. PMID 19956343 DOI: 10.1053/J.Scrs.2008.09.007  0.406
2008 Yen-Revollo JL, Auman JT, McLeod HL. Race does not explain genetic heterogeneity in pharmacogenomic pathways Pharmacogenomics. 9: 1639-1645. PMID 19018720 DOI: 10.2217/14622416.9.11.1639  0.36
2008 Peters EJ, McLeod HL. Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants. Pharmacogenomics. 9: 1573-7. PMID 19018710 DOI: 10.2217/14622416.9.11.1573  0.344
2008 Li L, Yu M, Jason RD, Shen C, Azzouz F, McLeod HL, Borges-Gonzales S, Nguyen A, Skaar T, Desta Z, Sweeney CJ, Flockhart DA. A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. Journal of Biopharmaceutical Statistics. 18: 1150-77. PMID 18991114 DOI: 10.1080/10543400802369038  0.317
2008 Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations Pharmacogenomics. 9: 1543-1546. PMID 18855540 DOI: 10.2217/14622416.9.10.1543  0.342
2008 Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, Mcleod H, Harnett PR, Brown R, Defazio A, Chenevix-Trench G. ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy Clinical Cancer Research. 14: 5594-5601. PMID 18765553 DOI: 10.1158/1078-0432.Ccr-08-0606  0.364
2008 Auman JT, Church R, Lee SY, Watson MA, Fleshman JW, Mcleod HL. Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. European Journal of Cancer (Oxford, England : 1990). 44: 1754-60. PMID 18653328 DOI: 10.1016/J.Ejca.2008.05.010  0.347
2008 Weiss ST, McLeod HL, Flockhart DA, Dolan ME, Benowitz NL, Johnson JA, Ratain MJ, Giacomini KM. Creating and evaluating genetic tests predictive of drug response. Nature Reviews. Drug Discovery. 7: 568-74. PMID 18587383 DOI: 10.1038/Nrd2520  0.335
2008 Auman JT, McLeod HL. Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity Drug Metabolism Reviews. 40: 303-315. PMID 18464047 DOI: 10.1080/03602530801952427  0.382
2008 Walko CM, McLeod HL. Will We Ever Be Ready for Blood Level–Guided Therapy? Journal of Clinical Oncology. 26: 2078-2079. PMID 18445837 DOI: 10.1200/Jco.2007.14.9609  0.338
2008 Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R, McLeod HL, Baiget M. Irinotecan pharmacogenetics: Influence of pharmacodynamic genes Clinical Cancer Research. 14: 1788-1796. PMID 18347181 DOI: 10.1158/1078-0432.Ccr-07-1472  0.36
2008 Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, ... ... McLeod HL, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clinical Pharmacology and Therapeutics. 84: 326-31. PMID 18305455 DOI: 10.1038/Clpt.2008.10  0.323
2008 Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clinical Cancer Research. 14: 8-13. PMID 18172246 DOI: 10.1158/1078-0432.Ccr-07-1225  0.357
2007 Oliveira E, Marsh S, Booven Dv, Amorim A, Prata M, McLeod H. Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics. 8: 703-712. PMID 18240903 DOI: 10.2217/14622416.8.7.703  0.347
2007 Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4528-35. PMID 17925548 DOI: 10.1200/Jco.2006.10.4752  0.418
2007 Jatoi A, Martenson JA, Foster NR, McLeod HL, Lair BS, Nichols F, Tschetter LK, Moore DF, Fitch TR, Alberts SR. Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). American Journal of Clinical Oncology. 30: 507-13. PMID 17921712 DOI: 10.1097/Coc.0B013E31805C139A  0.346
2007 Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. Journal of the National Cancer Institute. 99: 1290-5. PMID 17728214 DOI: 10.1093/Jnci/Djm115  0.353
2007 Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? European Journal of Cancer (Oxford, England : 1990). 43: 1011-6. PMID 17350823 DOI: 10.1016/J.Ejca.2007.01.030  0.395
2007 Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clinical Pharmacology and Therapeutics. 81: 328-45. PMID 17339863 DOI: 10.1038/Sj.Clpt.6100087  0.334
2007 Fukami T, Nakajima M, Yamanaka H, Fukushima Y, Mcleod HL, Yokoi T. A novel duplication type of CYP2A6 gene in African-American population. Drug Metabolism and Disposition. 35: 515-520. PMID 17267622 DOI: 10.1124/Dmd.106.013557  0.303
2007 Miller CR, McLeod HL. Pharmacogenomics of cancer chemotherapy-induced toxicity. The Journal of Supportive Oncology. 5: 9-14. PMID 17265780  0.4
2007 Marsh S, McLeod HL. Pharmacogenetics and oncology treatment for breast cancer. Expert Opinion On Pharmacotherapy. 8: 119-127. PMID 17257083 DOI: 10.1517/14656566.8.2.119  0.363
2007 Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics Journal. 7: 362-365. PMID 17224914 DOI: 10.1038/Sj.Tpj.6500434  0.387
2007 McLeod H. Graying anatomy? Toward molecular tumor characterization. Pharmacogenomics. 8: 15-16. PMID 17187503 DOI: 10.2217/14622416.8.1.15  0.378
2007 Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL, Sparreboom A. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clinical Pharmacology and Therapeutics. 81: 76-82. PMID 17186002 DOI: 10.1038/Sj.Clpt.6100011  0.338
2007 de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, Sparreboom A. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clinical Pharmacology and Therapeutics. 81: 42-9. PMID 17185998 DOI: 10.1038/Sj.Clpt.6100019  0.389
2007 Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, Viswanathan A, Govindan R, McLeod HL. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer Oncology Reports. 17: 853-857. DOI: 10.3892/Or.17.4.853  0.302
2007 Gandara DR, Kawaguchi T, Crowley JJ, Moon J, Kawahara M, Teramukai S, Williamson SK, Furuse K, McLeod HL, Mack PC. Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenomics Journal of Clinical Oncology. 25: 7500-7500. DOI: 10.1200/Jco.2007.25.18_Suppl.7500  0.353
2007 Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB Journal of Clinical Oncology. 25: 4508-4508. DOI: 10.1200/Jco.2007.25.18_Suppl.4508  0.3
2007 Hoskins JM, Goldberg RM, McLeod HL. Irinotecan-induced neutropenia and UGT1A1*28: Does dose matter? Journal of Clinical Oncology. 25: 4023-4023. DOI: 10.1200/Jco.2007.25.18_Suppl.4023  0.366
2007 Lee S, Watson M, Xu X, Wong CI, Iau P, Sukri N, Lim SE, Chuah B, McLeod H, Goh BC. Use of tumor gene expression signatures and drug-induced changes to discriminate early response in human breast cancer Journal of Clinical Oncology. 25: 2524-2524. DOI: 10.1200/Jco.2007.25.18_Suppl.2524  0.349
2006 Lanfear DE, Spertus JA, McLeod HL. Beta2-adrenergic receptor genotype predicts survival: implications and future directions. Journal of Cardiovascular Nursing. 21: 474-477. PMID 17293738 DOI: 10.1097/00005082-200611000-00011  0.311
2006 Engen RM, Marsh S, Booven DJV, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. Current Drug Targets. 7: 1641-1648. PMID 17168839 DOI: 10.2174/138945006779025446  0.394
2006 Ambrosone CB, Rebbeck TR, Morgan GJ, Albain KS, Calle EE, Evans WE, Hayes DF, Kushi LH, McLeod HL, Rowland JH, Ulrich CM. New developments in the epidemiology of cancer prognosis: Traditional and molecular predictors of treatment response and survival Cancer Epidemiology Biomarkers and Prevention. 15: 2042-2046. PMID 17119026 DOI: 10.1158/1055-9965.Epi-06-0827  0.333
2006 Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Shuldiner AR, Weinshilboum RM, Weiss ST. Pharmacogenomics: challenges and opportunities. Annals of Internal Medicine. 145: 749-57. PMID 17116919 DOI: 10.7326/0003-4819-145-10-200611210-00007  0.341
2006 Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6094-9. PMID 17062685 DOI: 10.1158/1078-0432.Ccr-06-1188  0.349
2006 O'Neil BH, McLeod HL. Thymidine phosphorylase and capecitabine: A predictive marker for therapy selection? Journal of Clinical Oncology. 24: 4051-4053. PMID 16943521 DOI: 10.1200/Jco.2006.07.1803  0.386
2006 Knoche E, McLeod HL, Graubert TA. Pharmacogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics. 7: 719-29. PMID 16886897 DOI: 10.2217/14622416.7.5.719  0.317
2006 Beitelshees AL, McLeod HL. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety Trends in Pharmacological Sciences. 27: 498-502. PMID 16876261 DOI: 10.1016/J.Tips.2006.07.005  0.348
2006 Beitelshees AL, McLeod HL. Clopidogrel Pharmacogenetics Promising Steps Towards Patient Care Arteriosclerosis, Thrombosis, and Vascular Biology. 26: 1681-1683. PMID 16857956 DOI: 10.1161/01.Atv.0000232583.51472.73  0.333
2006 Marsh S, King CR, McLeod HL, Paul J, Gifford G, Brown R. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4127; author reply 4. PMID 16818714 DOI: 10.1158/1078-0432.Ccr-06-0461  0.347
2006 Marsh S, Booven DJV, McLeod HL. Global pharmacogenetics: giving the genome to the masses Pharmacogenomics. 7: 625-631. PMID 16753009 DOI: 10.2217/14622416.7.4.625  0.347
2006 Ratain MJ, Miller AA, McLeod HL, Venook AP, Egorin MJ, Schilsky RL. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3612s-6s. PMID 16740794 DOI: 10.1158/1078-0432.Ccr-06-9008  0.365
2006 Fenske TS, McMahon C, Edwin D, Jarvis JC, Cheverud JM, Minn M, Mathews V, Bogue MA, Province MA, McLeod HL, Graubert TA. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Research. 66: 5029-38. PMID 16707424 DOI: 10.1158/0008-5472.Can-05-3404  0.329
2006 Marsh S, McLeod HL. Pharmacogenomics: from bedside to clinical practice Human Molecular Genetics. 15. PMID 16651374 DOI: 10.1093/Hmg/Ddl087  0.327
2006 Fukami T, Nakajima M, Sakai H, McLeod HL, Yokoi T. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. Pharmacogenomics Journal. 6: 401-412. PMID 16636685 DOI: 10.1038/Sj.Tpj.6500390  0.312
2006 Zhang W, Shannon W, Duncan J, Scheffer G, Scheper R, McLeod H. Expression of drug pathway proteins is independent of tumour type. The Journal of Pathology. 209: 213-219. PMID 16508919 DOI: 10.1002/Path.1955  0.348
2006 Zamboni WC, Ramanathan RK, McLeod HL, Mani S, Potter DM, Strychor S, Maruca LJ, King CR, Jung LL, Parise RA, Egorin MJ, Davis TA, Marsh S. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Investigational New Drugs. 24: 393-401. PMID 16505951 DOI: 10.1007/S10637-006-6335-5  0.321
2006 McLeod HL, Parodi L, Sargent DJ, Marsh S, Green E, Abreu P, Cisar LA, Goldberg RM. UGT1A1*28, toxicity and outcome in advanced colorectal cancer: Results from Trial N9741 Journal of Clinical Oncology. 24: 3520-3520. DOI: 10.1200/Jco.2006.24.18_Suppl.3520  0.32
2006 Goldberg RM, McLeod HL, Sargent DJ, Morton RF, Green EM, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. Genetic polymorphisms, toxicity, and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL, FOLFOX or IROX in Intergroup N9741 Journal of Clinical Oncology. 24: 3503-3503. DOI: 10.1200/Jco.2006.24.18_Suppl.3503  0.366
2006 Hoskins JM, Baiget M, Marcuello E, Altes A, McLeod HL. Irinotecan pharmacogenetics: The influence of pharmacodynamic genes Journal of Clinical Oncology. 24: 3075-3075. DOI: 10.1200/Jco.2006.24.18_Suppl.3075  0.307
2006 Pillot GA, Read WL, Hennenfent KL, Marsh S, Gao F, Viswanathan A, Cummings K, McLeod HL, Govindan R. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. Journal of Thoracic Oncology. 1: 972-978. DOI: 10.1016/S1556-0864(15)31629-4  0.379
2005 Morton RF, Sloan JA, Grothey A, Sargent DJ, McLeod H, Green EM, Fuchs C, Ramanathan RK, Williamson SK, Goldberg RM. A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8087. PMID 27946499 DOI: 10.1200/Jco.2005.23.16_Suppl.8087  0.302
2005 McLeod HL, Tan B, Malyapa R, Abbey E, Picus J, Myerson R, Zehnbauer B, Mutch M, Dietz D, Fleshman J. Genotype-guided neoadjuvant therapy for rectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3024. PMID 27945778 DOI: 10.1200/Jco.2005.23.16_Suppl.3024  0.348
2005 Grothey A, McLeod HL, Green EM, Sargent DJ, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP, Goldberg RM. Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3509. PMID 27944386 DOI: 10.1200/Jco.2005.23.16_Suppl.3509  0.387
2005 Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Viganò L, Locatelli A, Verweij J, Sparreboom A, McLeod HL. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8097-104. PMID 16299241 DOI: 10.1158/1078-0432.Ccr-05-1152  0.38
2005 Freimuth RR, Xiao M, Marsh S, Minton M, Addleman N, Van Booven DJ, McLeod HL, Kwok PY. Polymorphism discovery in 51 chemotherapy pathway genes. Human Molecular Genetics. 14: 3595-603. PMID 16239245 DOI: 10.1093/Hmg/Ddi387  0.386
2005 McLeod HL. Pharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms Clinical Infectious Diseases. 41: 225-237. PMID 16237646 DOI: 10.1086/431995  0.363
2005 Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R. CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer Cancer Research. 65: 8961-8967. PMID 16204069 DOI: 10.1158/0008-5472.Can-05-1187  0.325
2005 Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. β2-Adrenergic Receptor Genotype and Survival AmongPatients Receiving β-Blocker Therapy After an Acute Coronary Syndrome Jama. 294: 1526-1533. PMID 16189366 DOI: 10.1001/Jama.294.12.1526  0.302
2005 Hoskins JM, Marsh S, McLeod HL, Pai HV, Ravindranath V. Comment on "A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine" Drug Metabolism and Disposition. 33: 1564-1566. PMID 16166400 DOI: 10.1124/Dmd.105.005736  0.326
2005 Walgren RA, Meucci MA, McLeod HL. Pharmacogenomic discovery approaches: will the real genes please stand up? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7342-9. PMID 16145062 DOI: 10.1200/Jco.2005.03.0825  0.364
2005 Marsh S, King CR, Garsa AA, McLeod HL. Pyrosequencing of clinically relevant polymorphisms. Methods of Molecular Biology. 1015: 97-114. PMID 16100402 DOI: 10.1385/1-59259-957-5:097  0.304
2005 McLeod HL, Marsh S. Pharmacogenetics goes 3D. Nature Genetics. 37: 794-795. PMID 16049504 DOI: 10.1038/Ng0805-794  0.324
2005 Walgren RA, McLeod HL. Small inhibitory RNA--a tool for credentialing candidate genes. Pharmacogenomics. 6: 281-92. PMID 16013959 DOI: 10.1517/14622416.6.3.281  0.301
2005 Fukami T, Nakajima M, Higashi E, Yamanaka H, McLeod HL, Yokoi T. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity Biochemical Pharmacology. 70: 801-808. PMID 15993850 DOI: 10.1016/J.Bcp.2005.05.029  0.313
2005 Fox CA, Sapinoso LM, Zhang H, Zhang W, McLeod HL, Petroni GR, Mullick T, Moskaluk CA, Frierson HF, Hampton GM, Powell SM. Altered expression of TFF-1 and CES-2 in Barrett's Esophagus and associated adenocarcinomas. Neoplasia (New York, N.Y.). 7: 407-16. PMID 15967118 DOI: 10.1593/Neo.04715  0.305
2005 Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. British Journal of Cancer. 93: 46-53. PMID 15942626 DOI: 10.1038/Sj.Bjc.6602653  0.302
2005 Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The New England Journal of Medicine. 352: 2285-93. PMID 15930419 DOI: 10.1056/Nejmoa044503  0.325
2005 Fukami T, Nakajima M, Higashi E, Yamanaka H, Sakai H, McLeod HL, Yokoi T. Characterization Of Novel Cyp2A6 Polymorphic Alleles (Cyp2A6*18 And Cyp2A6*19) That Affect Enzymatic Activity Drug Metabolism and Disposition. 33: 1202-1210. PMID 15900015 DOI: 10.1124/Dmd.105.004994  0.306
2005 Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. Bmc Medical Genetics. 6: 19. PMID 15882469 DOI: 10.1186/1471-2350-6-19  0.315
2005 Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, Gatchel SK, Gage BF. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thrombosis and Haemostasis. 93: 700-5. PMID 15841315 DOI: 10.1160/Th04-08-0542  0.322
2005 Kidd EA, Yu J, Li X, Shannon WD, Watson MA, McLeod HL. Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2612-9. PMID 15814641 DOI: 10.1158/1078-0432.Ccr-04-1258  0.35
2005 Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clinical Pharmacokinetics. 44: 279-304. PMID 15762770 DOI: 10.2165/00003088-200544030-00005  0.318
2005 Yu J, Shannon WD, Watson MA, McLeod HL. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2053-62. PMID 15756032 DOI: 10.1158/1078-0432.Ccr-04-1254  0.33
2005 Tan BR, McLeod HL. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer Seminars in Oncology. 32: 113-119. PMID 15726513 DOI: 10.1053/J.Seminoncol.2004.09.029  0.376
2005 Meucci MA, Marsh S, Watters JW, McLeod HL. CEPH individuals are representative of the European American population: implications for pharmacogenetics. Pharmacogenomics. 6: 59-63. PMID 15723606 DOI: 10.1517/14622416.6.1.59  0.315
2005 Glasgow SC, Yu J, Carvalho LP, Shannon WD, Fleshman JW, McLeod HL. Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. British Journal of Cancer. 92: 259-264. PMID 15655543 DOI: 10.1038/Sj.Bjc.6602330  0.385
2005 Freimuth RR, Stormo GD, McLeod HL. PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis. Human Mutation. 25: 110-7. PMID 15643605 DOI: 10.1002/Humu.20123  0.316
2005 King CR, Yu J, Freimuth RR, McLeod HL, Marsh S. Interethnic variability of ERCC2 polymorphisms. Pharmacogenomics Journal. 5: 54-59. PMID 15534626 DOI: 10.1038/Sj.Tpj.6500283  0.325
2005 Cai S, Garbow JR, Culverhouse R, Church RD, Zhang W, Shannon WD, McLeod HL. A mouse model for developing treatment for secondary liver tumors International Journal of Oncology. 27: 113-120. DOI: 10.3892/Ijo.27.1.113  0.315
2005 Marsh S, Somlo G, McLeod HL, Li X, Frankel P, King CR, Shannon WD, Synold TW. Pharmacogenetic analysis of paclitaxel in breast cancer Journal of Clinical Oncology. 23: 3058-3058. DOI: 10.1200/Jco.2005.23.16_Suppl.3058  0.365
2005 Sparreboom A, Marsh S, Henningsson A, Karlsson MO, Garsa A, Loos WJ, Verweij J, McLeod HL. Effect of genetic variants in CYP2C8, CYP3A4, CYP3A5, and ABCB1 on paclitaxel pharmacokinetics Journal of Clinical Oncology. 23: 2019-2019. DOI: 10.1200/Jco.2005.23.16_Suppl.2019  0.375
2005 Gage BF, Eby CS, Johnson JA, Rieder MJ, Ridker PM, Rettie AE, Aquilante C, Milligan PE, Marsh S, Voora D, Langaee T, Veenstra DL, Birman-Deych E, Glynn R, Nickerson DA, ... McLeod HL, et al. Use of Pharmacogenetics and Clinical Factors To Predict the Maintenance Dose of Warfarin. Blood. 106: 550-550. DOI: 10.1182/Blood.V106.11.550.550  0.363
2005 Edwin D, Fenske TS, McMahon C, Mathews V, Bogue M, Province M, Cheverud J, McLeod H, Graubert TA. Susceptibility to Alkylator-Induced Cancer Is a Heritable Trait. Blood. 106: 3266-3266. DOI: 10.1182/Blood.V106.11.3266.3266  0.388
2004 Glasgow SC, Yu J, Linehan DC, Watson MA, McLeod HL. Modeling the response of colorectal cancer (CRC) to common chemotherapy using multivariate gene expression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2008. PMID 28015789 DOI: 10.1200/Jco.2004.22.14_Suppl.2008  0.334
2004 Read WL, Toles L, Romvari E, Adkins D, McLeod H, Govindan R. Phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer (NSCLC): Updated results of an ongoing study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7364. PMID 28015158 DOI: 10.1200/Jco.2004.22.14_Suppl.7364  0.33
2004 Sloan JA, McLeod H, Sargent D, Zhao X, Fuchs C, Ramanathan R, Williamson S, Findlay B, Morton R, Goldberg RM. Preliminary evidence of relationship between genetic markers and oncology patient quality of life (QOL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 5. PMID 28014162 DOI: 10.1200/Jco.2004.22.14_Suppl.5  0.311
2004 Watters JW, McLeod HL. Candidate gene selection in pharmacogenomics: biology leads the way. Pharmacogenomics. 5: 1019-22. PMID 15584871 DOI: 10.1517/14622416.5.8.1019  0.309
2004 Mauritz R, Beumer IJ, Marsh S, McLeod HL, Smid K, van Groeningen CJ, Pinedo HM, Peters GJ. Polymorphism of the thymidylate synthase gene and thymidylate synthase levels in colon cancer cell lines and different tissues of colorectal cancer patients. Nucleosides, Nucleotides & Nucleic Acids. 23: 1381-4. PMID 15571263 DOI: 10.1081/Ncn-200027634  0.373
2004 Rooney PH, Boonsong A, McFadyen MC, McLeod HL, Cassidy J, Curran S, Murray GI. The candidate oncogene ZNF217 is frequently amplified in colon cancer. The Journal of Pathology. 204: 282-8. PMID 15476264 DOI: 10.1002/Path.1632  0.338
2004 Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, Kwok PY, McLeod HL. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics. 84: 661-8. PMID 15475243 DOI: 10.1016/J.Ygeno.2004.07.008  0.348
2004 Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity Pharmacogenomics. 5: 835-843. PMID 15469406 DOI: 10.1517/14622416.5.7.835  0.402
2004 Thomas FJ, McLeod HL, Watters JW. Pharmacogenomics: the influence of genomic variation on drug response. Current Topics in Medicinal Chemistry. 4: 1399-409. PMID 15379653 DOI: 10.2174/1568026043387638  0.368
2004 Jong FAd, Marsh S, Mathijssen RHJ, King C, Verweij J, Sparreboom A, McLeod HL. ABCG2 Pharmacogenetics: Ethnic Differences in Allele Frequency and Assessment of Influence on Irinotecan Disposition Clinical Cancer Research. 10: 5889-5894. PMID 15355921 DOI: 10.1158/1078-0432.Ccr-04-0144  0.367
2004 Marsh S, King CR, Ahluwalia R, McLeod HL. Distribution of ITPA P32T alleles in multiple world populations. Journal of Human Genetics. 49: 579-81. PMID 15322947 DOI: 10.1007/S10038-004-0183-Y  0.337
2004 Watters JW, Kraja A, Meucci MA, Province MA, McLeod HL. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America. 101: 11809-14. PMID 15282376 DOI: 10.1073/Pnas.0404580101  0.345
2004 Lanfear DE, Marsh S, Cresci S, Shannon WD, Spertus JA, McLeod HL. Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans. Journal of the American College of Cardiology. 44: 165-167. PMID 15234427 DOI: 10.1016/J.Jacc.2004.03.053  0.321
2004 Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clinical Pharmacology and Therapeutics. 76: 38-44. PMID 15229462 DOI: 10.1016/J.Clpt.2004.03.003  0.312
2004 Nakajima M, Yoshida R, Fukami T, McLeod HL, Yokoi T. Novel human CYP2A6 alleles confound gene deletion analysis. Febs Letters. 569: 75-81. PMID 15225612 DOI: 10.1016/J.Febslet.2004.05.053  0.304
2004 McLeod HL, King CR, Marsh S. Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies. Clinical Colorectal Cancer. 4. PMID 15212705 DOI: 10.3816/Ccc.2004.S.007  0.382
2004 Ranganathan P, Culverhouse R, Marsh S, Ahluwalia R, Shannon WD, Eisen S, McLeod HL. Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics. 5: 559-69. PMID 15212592 DOI: 10.1517/14622416.5.5.559  0.313
2004 Quirk E, McLeod H, Powderly W. The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 39: 98-106. PMID 15206060 DOI: 10.1086/421557  0.304
2004 Voora D, McLeod HL, Eby C, Gage BF. Use of pharmacogenetics to guide warfarin therapy Drugs of Today. 40: 247-257. PMID 15148533 DOI: 10.1358/Dot.2004.40.3.820088  0.379
2004 Sparreboom A, Marsh S, Mathijssen RHJ, Verweij J, McLeod HL. Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Investigational New Drugs. 22: 285-289. PMID 15122075 DOI: 10.1023/B:Drug.0000026254.97350.Fe  0.376
2004 Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, Yokoi T. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics. 14: 329-332. PMID 15115919 DOI: 10.1097/00008571-200405000-00008  0.312
2004 Watters JW, Zhang W, Meucci MA, Hou W, Ma MK, McLeod HL. Analysis of variation in mouse TPMT genotype, expression and activity. Pharmacogenetics. 14: 247-54. PMID 15083069 DOI: 10.1097/00008571-200404000-00004  0.328
2004 Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1564-71. PMID 15051756 DOI: 10.1200/Jco.2004.08.186  0.34
2004 McLeod HL. Drug pathways: moving beyond single gene pharmacogenetics. Pharmacogenomics. 5: 139-141. PMID 15016603 DOI: 10.1517/Phgs.5.2.139.27486  0.378
2004 McLeod HL, Watters JW. Irinotecan pharmacogenetics: is it time to intervene? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1356-9. PMID 15007084 DOI: 10.1200/Jco.2004.01.950  0.405
2004 Freeman BD, McLeod HL. Challenges of implementing pharmacogenetics in the critical care environment Nature Reviews Drug Discovery. 3: 88-93. PMID 14708023 DOI: 10.1038/Nrd1285  0.313
2004 Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thrombosis and Haemostasis. 91: 87-94. PMID 14691573 DOI: 10.1160/Th03-06-0379  0.325
2004 Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Liang J, McLeod HL, Atkins D. Gene expression profiling to predict recurrent Dukes' B colon cancer Journal of Clinical Oncology. 22: 9555-9555. DOI: 10.1200/Jco.2004.22.90140.9555  0.353
2004 Kolesar JM, Breunig A, Miller J, Stephenson P, McLeod H, Marsh S, Keller S, Johnson D, Schiller JH. CYP3A5*3 and CYP3A4*1B polymorphisms are associated and more frequent in NSCLC tumors than in normal volunteers Journal of Clinical Oncology. 22: 2016-2016. DOI: 10.1200/Jco.2004.22.90140.2016  0.336
2004 Glasgow SC, Yu J, Carvalho L, Shannon W, Fleshman J, McLeod H. Unfavorable expression of pharmacologic markers in mucinous colorectal cancer (CRC) Journal of the American College of Surgeons. 199: 80-81. DOI: 10.1016/J.Jamcollsurg.2004.05.175  0.307
2003 McLeod HL, Church RD. Molecular predictors of prognosis and response to therapy in colorectal cancer. Cancer Chemotherapy and Biological Response Modifiers Annual. 21: 791-801. PMID 15338774 DOI: 10.1016/S0921-4410(03)21037-1  0.321
2003 Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: Polymorphisms, pathways and beyond Nature Reviews Cancer. 3: 912-920. PMID 14740638 DOI: 10.1038/Nrc1233  0.406
2003 McLeod HL, Yu J. Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Investigation. 21: 630-640. PMID 14533451 DOI: 10.1081/Cnv-120022384  0.401
2003 Ahluwalia R, Freimuth R, McLeod HL, Marsh S. Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clinical Chemistry. 49: 1661-4. PMID 14500593 DOI: 10.1373/49.10.1661  0.388
2003 Watters JW, Kloss EF, Link DC, Graubert TA, McLeod HL. A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. Journal of Applied Physiology (Bethesda, Md. : 1985). 95: 1352-60. PMID 12970373 DOI: 10.1152/Japplphysiol.00214.2003  0.331
2003 Church RD, Fleshman JW, McLeod HL. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. British Journal of Surgery. 90: 1055-1067. PMID 12945071 DOI: 10.1002/Bjs.4297  0.355
2003 Rose CM, Marsh S, Ameyaw MM, McLeod HL. Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Methods in Molecular Medicine. 85: 225-37. PMID 12710211 DOI: 10.1385/1-59259-380-1:225  0.323
2003 Plasencia C, Rooney PH, Taron M, Martinez-Balibrea E, McLeod HL, Abad A. Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms. International Journal of Oncology. 22: 945-953. PMID 12684658 DOI: 10.3892/Ijo.22.5.945  0.306
2003 Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. British Journal of Cancer. 88: 928-932. PMID 12644831 DOI: 10.1038/Sj.Bjc.6600825  0.337
2003 Watters JW, McLeod HL. Cancer pharmacogenomics: current and future applications. Biochimica Et Biophysica Acta. 1603: 99-111. PMID 12618310 DOI: 10.1016/S0304-419X(03)00003-9  0.432
2003 Evans WE, McLeod HL. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects The New England Journal of Medicine. 348: 538-549. PMID 12571262 DOI: 10.1056/Nejmra020526  0.316
2003 Watters JW, McLeod HL. Using genome-wide mapping in the mouse to identify genes that influence drug response. Trends in Pharmacological Sciences. 24: 55-8. PMID 12559764 DOI: 10.1016/S0165-6147(02)00044-5  0.338
2002 Watters JW, McLeod HL. Recent advances in the pharmacogenetics of cancer chemotherapy. Current Opinion in Molecular Therapeutics. 4: 565-71. PMID 12596358  0.311
2002 Boonsong A, Curran S, McKay JA, Cassidy J, Murray GI, McLeod HL. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Human Pathology. 33: 1114-9. PMID 12454816 DOI: 10.1053/Hupa.2002.129202  0.308
2002 Watters JW, McLeod HL. Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy. Pharmacogenomics. 3: 781-90. PMID 12437480 DOI: 10.1517/14622416.3.6.781  0.341
2002 Ma MK, Woo MH, McLeod HL. Genetic Basis of Drug Metabolism American Journal of Health-System Pharmacy. 59: 2061-2069. PMID 12434718 DOI: 10.1093/Ajhp/59.21.2061  0.382
2002 Marsh S, Kwok P, McLeod HL. SNP databases and pharmacogenetics: great start, but a long way to go. Human Mutation. 20: 174-9. PMID 12203989 DOI: 10.1002/Humu.10115  0.307
2002 McLeod HL. Individualized cancer therapy: molecular approaches to the prediction of tumor response Expert Review of Anticancer Therapy. 2: 113-119. PMID 12113060 DOI: 10.1586/14737140.2.1.113  0.351
2002 Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochimica Et Biophysica Acta. 1587: 194-205. PMID 12084461 DOI: 10.1016/S0925-4439(02)00082-0  0.308
2002 McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. Pharmacogenomics. 3: 89-98. PMID 11966406 DOI: 10.1517/14622416.3.1.89  0.366
2002 McKay JA, Loane J, Ross VG, Ameyaw M, Murray GI, Cassidy J, McLeod HL. c-erbB-2 is not a major factor in the development of colorectal cancer. British Journal of Cancer. 86: 568-573. PMID 11870539 DOI: 10.1038/Sj.Bjc.6600127  0.349
2002 Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. International Journal of Oncology. 21: 1119-1124. DOI: 10.3892/Ijo.21.5.1119  0.305
2001 Marsh S, McLeod HL. Thymidylate synthase pharmacogenetics in colorectal cancer. Clinical Colorectal Cancer. 1: 175-178. PMID 12450432 DOI: 10.3816/Ccc.2001.N.018  0.429
2001 Rooney PH, Boonsong A, McKay JA, Marsh S, Stevenson DAJ, Murray GI, Curran S, Haites NE, Cassidy J, McLeod HL. Colorectal cancer genomics: evidence for multiple genotypes which influence survival British Journal of Cancer. 85: 1492-1498. PMID 11720434 DOI: 10.1054/Bjoc.2001.2095  0.325
2001 McLeod HL. Pharmacogenetics: more than skin deep. Nature Genetics. 29: 247-248. PMID 11687789 DOI: 10.1038/Ng1101-247  0.342
2001 McFadyen MCE, Cruickshank ME, Miller ID, McLeod HL, Melvin WT, Haites NE, Parkin D, Murray GI. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. British Journal of Cancer. 85: 242-246. PMID 11461084 DOI: 10.1054/Bjoc.2001.1907  0.359
2001 Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. International Journal of Oncology. 19: 383-386. PMID 11445856 DOI: 10.3892/Ijo.19.2.383  0.412
2001 McFadyen MCE, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochemical Pharmacology. 62: 207-212. PMID 11389879 DOI: 10.1016/S0006-2952(01)00643-8  0.326
2001 Kumagai K, Hiyama K, Ishioka S, Sato H, Yamanishi Y, Mcleod HL, Konishi F, Maeda H, Yamakido M. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics. 11: 275-278. PMID 11337944 DOI: 10.1097/00008571-200104000-00012  0.32
2001 McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annual Review of Pharmacology and Toxicology. 41: 101-121. PMID 11264452 DOI: 10.1146/Annurev.Pharmtox.41.1.101  0.343
2001 Chapman AD, Pritchard SC, Yap WW, Rooney PH, Cockburn JS, Hutcheon AW, Nicolson MC, Kerr KM, McLeod HL. Primary pulmonary osteosarcoma: case report and molecular analysis. Cancer. 91: 779-84. PMID 11241246 DOI: 10.1002/1097-0142(20010215)91:4<779::Aid-Cncr1064>3.0.Co;2-J  0.319
2001 Balciuniene J, Syvänen AC, McLeod HL, Pettersson U, Jazin EE. The geographic distribution of monoamine oxidase haplotypes supports a bottleneck during the dispersion of modern humans from Africa. Journal of Molecular Evolution. 52: 157-63. PMID 11231895 DOI: 10.1007/S002390010144  0.322
2001 Dusseau C, Murray GI, Keenan RA, O'Kelly T, Krokan HE, McLeod HL. Analysis of uracil DNA glycosylase in human colorectal cancer International Journal of Oncology. 18: 393-399. PMID 11172609 DOI: 10.3892/Ijo.18.2.393  0.313
2001 Bissett D, McLeod HL, Sheedy B, Collier M, Pithavala Y, Paradiso L, Pitsiladis M, Cassidy J. Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. British Journal of Cancer. 84: 308-12. PMID 11161393 DOI: 10.1054/Bjoc.2000.1601  0.321
2001 McKay JA, Githang’a J, Indalo A, Li T, Liu X, Ameyaw M, Ofori‐Adjei D, McLeod HL. Distinct differences in a cyclin D1 single nucleotide polymorphism between ethnic groups Genescreen. 1: 139-142. DOI: 10.1046/J.1466-9218.2001.00014.X  0.336
2001 Marsh S, McLeod HL. Drugs in the postgenomic era Trends in Molecular Medicine. 7: 532. DOI: 10.1016/S1471-4914(01)02192-X  0.331
2000 Ameyaw MM, Thornton N, McLeod HL. Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. Journal of the National Cancer Institute. 92: 1947. PMID 11106692 DOI: 10.1093/Jnci/92.23.1947  0.319
2000 Marsh S, Ameyaw MM, Githang'a J, Indalo A, Ofori-Adjei D, McLeod HL. Novel thymidylate synthase enhancer region alleles in African populations. Human Mutation. 16: 528. PMID 11102983 DOI: 10.1002/1098-1004(200012)16:6<528::Aid-Humu11>3.0.Co;2-W  0.32
2000 Ameyaw MM, Syvänen AC, Ulmanen I, Ofori-Adjei D, McLeod HL. Pharmacogenetics of catechol-O-methyltransferase: frequency of low activity allele in a Ghanaian population. Human Mutation. 16: 445-6. PMID 11058906 DOI: 10.1002/1098-1004(200011)16:5<445::Aid-Humu13>3.0.Co;2-3  0.313
2000 Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, Féty-Deporte R, Lafont T, Gamelin E, Bugat R, Canal P, Chatelut E. Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clinical Pharmacology and Therapeutics. 68: 270-9. PMID 11014408 DOI: 10.1067/Mcp.2000.109352  0.307
2000 McLeod HL, McKay JA, Collie-Duguid ESR, Cassidy J. Therapeutic opportunities from tumour biology in metastatic colon cancer. European Journal of Cancer. 36: 1706-1712. PMID 10959056 DOI: 10.1016/S0959-8049(00)00150-7  0.347
2000 Boonsong A, Marsh S, Rooney PH, Stevenson DAJ, Cassidy J, McLeod HL. Characterization of the topoisomerase I locus in human colorectal cancer. Cancer Genetics and Cytogenetics. 121: 56-60. PMID 10958942 DOI: 10.1016/S0165-4608(00)00242-9  0.305
2000 McKay JA, Lloret C, Murray GI, Johnston PG, Bicknell R, Ahmed FY, Cassidy J, McLeod HL. Application of the enrichment approach to identify putative markers of response to 5-fluorouracil therapy in advanced colorectal carcinomas. International Journal of Oncology. 17: 153-161. PMID 10853033 DOI: 10.3892/Ijo.17.1.153  0.373
2000 Collie-Duguid ESR, Etienne MC, Milano G, Mcleod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 10: 217-223. PMID 10803677 DOI: 10.1097/00008571-200004000-00002  0.369
2000 Collie-Duguid ESR, Johnston SJ, Powrie RH, Milano G, Etienne MC, Rochat B, Watson GC, McLeod HL. Cloning and Initial Characterization of the Human DPYD Gene Promoter Biochemical and Biophysical Research Communications. 271: 28-35. PMID 10777676 DOI: 10.1006/Bbrc.2000.2593  0.374
2000 McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 14: 567-572. PMID 10764140 DOI: 10.1038/Sj.Leu.2401723  0.382
2000 Milano G, McLeod HL. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? European Journal of Cancer. 36: 37-42. PMID 10741292 DOI: 10.1016/S0959-8049(99)00211-7  0.328
1999 McLeod HL, Milne LH, Johnston SJ. 5-Fluorouracil Metabolizing Enzymes Methods in Molecular Medicine. 28: 111-120. PMID 21374032 DOI: 10.1385/1-59259-687-8:111  0.332
1999 Mcleod HL, Pritchard SC, Githang'a J, Indalo A, Ameyaw M-, Powrie RH, Booth L, Collie-Duguid ESR. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals Pharmacogenetics. 9: 773-776. PMID 10634140 DOI: 10.1097/00008571-199912000-00012  0.322
1999 Ishioka S, Hiyama K, Sato H, Yamanishi Y, Mcleod HL, Kumagai K, Maeda H, Yamakido M. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Internal Medicine. 38: 944-947. PMID 10628931 DOI: 10.2169/Internalmedicine.38.944  0.334
1999 Marsh S, Collie-Duguid ESR, Li T, Liu X, McLeod HL. Ethnic Variation in the Thymidylate Synthase Enhancer Region Polymorphism Among Caucasian and Asian Populations Genomics. 58: 310-312. PMID 10373329 DOI: 10.1006/Geno.1999.5833  0.354
1999 McLeod HL, Coulthard S, Thomas AE, Pritchard SC, King DJ, Richards SM, Eden OB, Hall AG, Gibson BE. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. British Journal of Haematology. 105: 696-700. PMID 10354134 DOI: 10.1046/J.1365-2141.1999.01416.X  0.368
1999 Collie-Duguid ESR, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, Mcleod HL. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 9: 37-42. PMID 10208641 DOI: 10.1097/00008571-199902000-00006  0.311
1999 Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Human Molecular Genetics. 8: 367-70. PMID 9931345 DOI: 10.1093/Hmg/8.2.367  0.304
1999 McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer British Journal of Cancer. 79: 191-203. PMID 9888457 DOI: 10.1038/Sj.Bjc.6690033  0.306
1998 Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ESR, Reid DM. Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine Annals of Internal Medicine. 129: 716-718. PMID 9841604 DOI: 10.7326/0003-4819-129-9-199811010-00007  0.335
1998 Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, Kuilenburg ABv, Gennip AHv, McLeod HL. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects British Journal of Clinical Pharmacology. 46: 151-156. PMID 9723824 DOI: 10.1046/J.1365-2125.1998.00751.X  0.334
1998 Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P, Gonzalez FJ. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics. 51: 391-400. PMID 9721209 DOI: 10.1006/Geno.1998.5379  0.33
1998 McLeod HL. Clinically relevant drug–drug interactions in oncology British Journal of Clinical Pharmacology. 45: 539-544. PMID 9663808 DOI: 10.1046/J.1365-2125.1998.00719.X  0.334
1998 Ridge S, Sludden J, Wei X, Sapone A, Brown O, Hardy S, Canney P, Fernandez-Salguero P, Gonzalez F, Cassidy J, McLeod H. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer British Journal of Cancer. 77: 497-500. PMID 9472650 DOI: 10.1038/Bjc.1998.79  0.301
1997 McLeod HL. Therapeutic drug monitoring opportunities in cancer therapy. Pharmacology & Therapeutics. 74: 39-54. PMID 9336015 DOI: 10.1016/S0163-7258(96)00201-X  0.369
1996 Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. Journal of Clinical Investigation. 98: 610-615. PMID 8698850 DOI: 10.1172/Jci118830  0.358
Show low-probability matches.